Roth Capital Reiterates “Buy” Rating for Nuvectis Pharma (NASDAQ:NVCT)

Nuvectis Pharma (NASDAQ:NVCTGet Rating)‘s stock had its “buy” rating restated by Roth Capital in a research note issued on Sunday, Zacks.com reports.

Separately, HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of Nuvectis Pharma in a research note on Wednesday, April 13th.

NASDAQ:NVCT opened at $9.58 on Friday. The company’s 50 day moving average price is $7.66. Nuvectis Pharma has a 1-year low of $3.08 and a 1-year high of $11.04.

In related news, CEO Ron Bentsur purchased 7,000 shares of the company’s stock in a transaction that occurred on Thursday, March 17th. The shares were purchased at an average price of $7.63 per share, with a total value of $53,410.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders purchased a total of 19,000 shares of company stock worth $128,650 in the last three months.

Nuvectis Pharma Company Profile (Get Rating)

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases.

Read More

Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.